LIXTE Biotechnology to Seek Investor Meetings at DealFlow Discovery Conference
Event summary
- LIXTE Biotechnology will attend the DealFlow Discovery Conference in Atlantic City on January 28-29, 2026.
- CEO Geordan Pursglove will conduct one-on-one investor meetings during the event.
- LIXTE is a clinical-stage pharmaceutical company focused on cancer therapies, including its lead compound LB-100.
- The company also develops proton therapy systems through its subsidiary Liora Technologies.
The big picture
LIXTE's participation in the DealFlow Discovery Conference underscores its push for investor engagement amid a competitive biotech landscape. The company's focus on activation lethality and proton therapy positions it in niche but growing segments of cancer treatment. Success in securing funding will be critical for advancing its clinical pipeline and commercializing its technologies.
What we're watching
- Funding Progress
- Whether LIXTE can secure significant investor interest during the conference to advance its clinical trials.
- Clinical Milestones
- The pace at which LIXTE's proof-of-concept trials for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma progress.
- Technology Development
- How Liora Technologies' LiGHT System will differentiate itself in the proton therapy market.
Related topics